Literature DB >> 12453978

Cardiac autonomic nervous dysfunction in diabetic patients with a mitochondrial DNA mutation: assessment by heart rate variability.

Yukihiko Momiyama1, Yoshihiko Suzuki, Masako Ohtomo, Yoshihito Atsumi, Kempei Matsuoka, Fumitaka Ohsuzu, Mitsuru Kimura.   

Abstract

OBJECTIVE: To elucidate the degree and characteristics of cardiac autonomic nervous dysfunction in diabetic patients associated with a mitochondrial DNA mutation at base pair 3243. RESEARCH DESIGN AND METHODS: We investigated heart rate variability using 24-h Holter monitoring in 10 diabetic patients with the mutation compared with 55 ordinary diabetic patients and 45 nondiabetic control subjects.
RESULTS: Age and sex were similar in the three groups. Between patients with the mutation and ordinary diabetic patients, the duration of diabetes and blood glycemic levels were not different. In the time domain analysis of heart rate variability, patients with the mutation and ordinary diabetic patients had significantly smaller SDNN index and pNN50 than control subjects. Compared with ordinary diabetic patients, patients with the mutation had smaller SDNN index (P < 0.02), but rMSSD and pNN50 were not different. In the frequency domain analysis, total, low frequency (LF), and high frequency (HF) spectra were significantly smaller in patients with the mutation and ordinary diabetic patients than in control subjects. Compared with ordinary diabetic patients, patients with the mutation had smaller total and LF spectra (P < 0.02). However, HF spectra were not significantly different. Notably, the LF/HF spectra ratio was lower in patients with the mutation than in ordinary diabetic patients and control subjects (P < 0.05), but this ratio was similar in ordinary diabetic patients and control subjects.
CONCLUSIONS: Our results suggest that diabetic patients with the mitochondrial DNA mutation have more severely impaired cardiac autonomic nervous function with sympathovagal imbalance, as compared with ordinary diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453978     DOI: 10.2337/diacare.25.12.2308

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

Review 1.  Mitochondrial disease and endocrine dysfunction.

Authors:  Jasmine Chow; Joyeeta Rahman; John C Achermann; Mehul T Dattani; Shamima Rahman
Journal:  Nat Rev Endocrinol       Date:  2016-10-07       Impact factor: 43.330

Review 2.  Autonomic aspects of arrhythmogenesis: the enduring and the new.

Authors:  Richard L Verrier; Charles Antzelevitch
Journal:  Curr Opin Cardiol       Date:  2004-01       Impact factor: 2.161

3.  Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease.

Authors:  Matthew G D Bates; Jane H Newman; Djordje G Jakovljevic; Kieren G Hollingsworth; Charlotte L Alston; Pawel Zalewski; Jacek J Klawe; Andrew M Blamire; Guy A MacGowan; Bernard D Keavney; John P Bourke; Andrew Schaefer; Robert McFarland; Julia L Newton; Douglass M Turnbull; Robert W Taylor; Michael I Trenell; Gráinne S Gorman
Journal:  Int J Cardiol       Date:  2013-06-03       Impact factor: 4.164

Review 4.  The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy.

Authors:  Li-Chan Tao; Ting-Ting Wang; Lu Zheng; Fei Hua; Jian-Jun Li
Journal:  Biomol Ther (Seoul)       Date:  2022-04-12       Impact factor: 4.231

5.  Ethoxyquin is neuroprotective and partially prevents somatic and autonomic neuropathy in db/db mouse model of type 2 diabetes.

Authors:  Ying Liu; Yuan Sun; Osefame Ewaleifoh; Josh Wei; Ruifa Mi; Jing Zhu; Ahmet Hoke; Michael Polydefkis
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

6.  Evidence of cardiovascular autonomic impairment in mitochondrial disorders.

Authors:  Rita Di Leo; Olimpia Musumeci; Cesare de Gregorio; Antonio Recupero; Patrizia Grimaldi; Corrado Messina; Sebastiano Coglitore; Giuseppe Vita; Antonio Toscano
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 6.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.